NCT02158858 2025-10-08A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative MalignanciesConstellation PharmaceuticalsPhase 1/2 Completed336 enrolled